Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05790733
Other study ID # CHU de Rennes
Secondary ID 2023-A00062-43
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 1, 2024
Est. completion date February 1, 2026

Study information

Verified date November 2023
Source Rennes University Hospital
Contact Magali GRANGER, nurse
Phone 02 99 28 43 21
Email magali.granger@chu-rennes.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Caloric intake is a determining factor in patients with hematological malignancies and hospitalized for prolonged aplasia following chemotherapy. The nutritional supplement is administered either parenterally or enterally through the placement of a nasogastric sonde (NGS). This last option has shown its advantage compared to parenteral nutrition in terms of preventing infections, the incidence of graft-versus-host disease in allograft patients, and the quality of resumption of oral nutrition during of returning home. NGS allows the administration of an intake of 2000 calories/day, deemed necessary to mitigate the risk of undernutrition in patients hospitalized for more than 3 weeks and in the majority of cases unable to eat enough food mainly due to chemotherapy-induced mucositis. . The choice between enteral feeding by NGS and parenteral nutrition is the subject of controversial studies, with each team choosing one of the two options. The installation of the NGS is often recognized as a traumatic gesture for patients but also invasive by caregivers. The patient's anxiety, the intrusive and traumatic nature of the NGS can sometimes result in a failure of the gesture, a secondary refusal of the patient, or a reluctance of the caregiver to proceed with the gesture. Since 2013, NGS have been placed with the assistance of the nurse who practices hypnosis in the hematology department of the Rennes University Hospital. This invites the patient to pose his SNG without local anesthesia and in a completely autonomous way. The patient is thus able to place the NGS again if necessary during his hospitalization, and during subsequent hospitalizations. A retrospective and monocentric study carried out at the University Hospital of Rennes in 38 patients showed that all were able to perform NGS independently thanks to the hypnotic approach. It was observed a real comfort for the patient, and moreover this technique did not add extra work for the staff. The patient becomes autonomous and actor of his care.


Description:

Strategy : Hypnosis versus standard way for the installation of an NGS. In the conventional arm, the nurse will place the NGS according to the recommendations of the French Health Authorities on the management of the induced pain. The patient is seated at 90 degrees. The nurse takes its landmarks on the NGS to be able to install the NGS at the correct landmark (it takes the SNG and measures "nose-ear, ear-stomach"). As part of this project, local anesthesia will be performed if the patient is part of the control arm and there will be none if he is part of the hypnosis arm. When the patient will be randomized in the hypnosis arm, he will place his NGS himself with a hypnotic accompaniment, described in appendix. This original project aims to evaluate the contribution of hypnosis in the installation of an NGS in patients hospitalized for the management of a malignant hemopathy for a period of at least 3 weeks. A group of patients will benefit from the autonomous installation of the NGS thanks to the assistance of a nurse hypnotherapist and will be compared to a group of patients for whom the NGS will be set up in a standard way. The main expected benefits of hypnosis for the patient include improved comfort and near absence of discomfort or pain during NGS placement, minimal anxiety and ultimately a benefit in terms of caloric intake administered during prolonged hospitalization.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 180
Est. completion date February 1, 2026
Est. primary completion date August 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient hospitalized for chemotherapy generating an aplasia lasting more than 8 days (hospitalization for 3 weeks) and for whom the insertion of an NGS is required and not yet attempted since admission to the hospital; - Age = 18 years; - Affiliated to a social security scheme; - Having signed a free, informed and written consent. Exclusion Criteria: - Pregnant or breastfeeding women; - Patient who refuses NGS; - Emergency surgery; - Patients consuming long-term opiates before surgery; - Substance addiction; - Patient at the end of life and/or in palliative care; - Patient unable to answer a questionnaire and/or unable to understand the rating scales; - Deaf and/or dumb patients; - Patients with psychiatric pathologies (schizophrenia, bipolarity); - Persons subject to legal protection (safeguard of justice, curatorship, guardianship), persons deprived of liberty.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Standard intubation
This involves the use of 5% Xylocaine nebulizer spray and a single-use cannula. The nurse checks its expiry date and that the quantity is sufficient to practice the 7 instillations in one nostril and the other 7 in the mouth. A waiting time is respected and the installation of the NGS can begin. She will also set up a fast for 2 hours after this local anesthesia.
Hypnosis
Hypnosis is a particular psychological state marked by the functioning of the individual at a level of attention other than the ordinary state of consciousness. It can, under certain conditions, give the appearance of sleep or somnambulism without sharing all the characteristics. As part of the treatment, hypnosis is widely used for pain control. The adverse effects reported are nil. One of its main benefits is improved patient comfort. Another benefit is the reduction of exposure to anesthetic products. The installation of the NGS with hypnosis will be carried out according to the protocol set out in appendix 4.

Locations

Country Name City State
France Rennes University Hospital Rennes Bretagne
France Tours University Hospital Tours

Sponsors (1)

Lead Sponsor Collaborator
Rennes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Comfort Patient comfort will be assessed by a simple, validated digital comfort scale. This scale is graduated from "0" (no comfort) to "10" (maximum conceivable comfort). This evaluation will be carried within 3 minutes following the end of the intubation, i.e. after having checked the correct location of the probe thanks to the presence of air blown in by a syringe with a conical tip, that the nurse will check with a stethoscope right after securing the SNG with a hypoallergenic dressing on the patient's chee Within 3 minutes after the end of the intubation
Secondary Pain visual analogue scale The patient's pain will be assessed by the visual analogue scale (VAS). This scale is graduated from "0" (no pain) to "10" (maximum pain imaginable). It will be performed immediately after the assessment of the comfort scale. Immediately after the assessment of the comfort scale (assessed within 3 minutes after the end of the intubation)
Secondary Anxiety The anxiety felt by the patient will be assessed by a simple and validated numerical scale. This scale is graduated from "0" (no anxiety) to "10" (maximum anxiety imaginable). It will be performed 10 minutes (+/- 3 minutes) before the biopsy procedure and repeated after the biopsy procedure (just after the pain assessment). 5 minutes (+/- 1 minute) before the NGS placement starts and repeated immediately after the procedure ends (just after the pain assessment)
Secondary Success or failure of the NGS placement according to the randomization arm Success or failure of the NGS placement after using the method (standard method versus hypnosis) given by the randomization arm During procedure
Secondary Number of failures The number of failures during the first NGS insertion according to the randomization arm with the need to switch to another NGS insertion procedure, or even the need to switch to parenteral nutrition (following repeated failures of the NGS). During procedure
Secondary Weight Weight at entry and exit from hospitalization in the hematology department. From date of admission to hospital in the hematology department up to date of the hospital discharge in the hematology department, assessed up to 3 months
Secondary Muscular strength Muscular strength assessed by means of a dynamometer at entry and exit from hospitalization in the hematology department From date of admission to hospital in the hematology department up to date of the hospital discharge in the hematology department, assessed up to 3 months
Secondary Total number of days of presence of the NGS The total number of days of presence of the NGS during the hospitalization time During the hospitalization time (up to 3 months)
Secondary Attempt or not of a new NGS intubation (in case of rejection of the first probe by vomiting) In case of rejection of the first probe by vomiting during hospitalization, attempt or not of a new NGS intubation From date of admission to hospital in the hematology department up to date of the hospital discharge in the hematology department, assessed up to 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT06376604 - Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies N/A
Completed NCT03753542 - Effect of Nurse-led Education on Parent's Anxiety and Depression on Managing Side Effects of Chemotherapy N/A
Not yet recruiting NCT05022628 - Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis Phase 4
Completed NCT04207359 - Effects of Creatine Supplementation in Breast Cancer Survivors N/A
Active, not recruiting NCT04489173 - TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer Phase 2
Completed NCT04173195 - Comfort Talk (CT) During Outpatient Chemotherapy N/A
Recruiting NCT06041477 - Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC Phase 3
Recruiting NCT05014399 - Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
Recruiting NCT03275194 - HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy Phase 2
Recruiting NCT04808466 - Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Phase 2
Recruiting NCT06421610 - OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion. Phase 1
Completed NCT05131490 - Effect on Adaptation to Cancer of Mobile Application Developed for Gynecological Cancer Patients N/A
Completed NCT04118322 - The Effect of Peppermint Oil on Nausea, Vomiting and Retching in Cancer Patients Undergoing Chemotherapy N/A
Recruiting NCT06043999 - Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients N/A
Recruiting NCT05515796 - Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors Phase 2
Not yet recruiting NCT04845490 - Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Phase 2
Recruiting NCT04989985 - S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma Phase 2
Recruiting NCT05424692 - Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer N/A
Recruiting NCT05992337 - New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
Enrolling by invitation NCT04027478 - Can Fasting Decrease the Side Effects of Chemotherapy? N/A